Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC Funds in Israel

Last updated: Apr 2024 A list of 50 VC funds that invest in Life science startups based in Israel. We rank investors based on the number of investments they made in Life science companies from Israel. We update this investor list every month.

Top 50 Life Science VC Funds in Israel

Investor	Life Science Israel investments
Integra Holdings	4
Sapir Venture Partners	3
Israel Innovation Authority	3
OrbiMed	3
Neo Ventures	3
Pitango VC	3
Takeda Ventures	2
Cancer Focus Fund	2
FutuRx	2
Pontifax	2
Arancia International	2
aMoon Fund	2
Minrav	2
Johnson & Johnson Robotics and Digital Solutions	2
Genesis Park	2
fresh.fund	2
PeakBridge	2
Morningside Venture Investments	1
Arkin Holdings	1
Remiges Ventures	1
HBL Hadasit Bio Holdings	1
ALIVE Israel HealthTech Fund	1
Life Science Angels	1
NextLeap Ventures	1
Angel	1
Bio Capital Impact Fund	1
OTV	1
Jerusalem Venture Partners (JVP)	1
Aries Holding BV	1
Sectoral Asset Management	1
Dementia Discovery Fund	1
First Star Ventures	1
Rationalwave Capital Partners	1
Stony Hill Corp	1
SICAR	1
Boehringer Ingelheim Venture Fund	1
RMGP Biopharma Investment Fund	1
Arix Bioscience	1
Talisman Capital Partners	1
Trust Ventures	1
Grove Ventures	1
Clal Biotechnology Industries	1
TPY Capital	1
Arba Finance Ltd.	1
RM Global Partners	1
M Ventures	1
Trendlines Group	1
3B Future Health Fund	1
Windham Venture Partners	1
Arc Impact	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Our expert team is the first to examine and evaluate the Hebrew University's biomedical breakthroughs. We then capitalize decades of experience - transforming the inventions into pioneering companies. Our golden eggs Ayana Pharma A late stage company with

Investment focus

Biotechnology, Pharmaceutical, Life Science
Seed, Series B, Series F
Israel

Portfolio highlights

BacoCure — BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients.
Splisense — Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried.
Rebiotic Rx — Develops nanotechnology-based antibiotics with the focus on resistant bacteria

Early Stage VC

Investment focus

Software, Biotechnology, Machine Learning
Seed, Pre-Seed, Series A
Israel, United States, United Kingdom

Portfolio highlights

Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
DeepCure — Pioneering a new frontier in drug development. DeepCure is building an AI engine for small-molecule drug discovery.
Genetika+ — Genetika+ is revolutionzing depression treatment. Using biological, medical and genetic data, GenetikaPlus develops personalized solution for every patient to help them recover better, faster.

The Israeli innovation agency, the Innovation Authority, was established in 1965 as the Office of the Chief Scientist of the Ministry of Industry and Trade and was designed as a body that supports R & D conducted in the framework of government research institutes. Industrial development in order to increase industrial exports of high-techproducts. The Chief Scientist focused on reducing the risk by participating in financing the project, which the private companies chose and led.

Investment focus

Health Care, Biotechnology, Medical Device
Grant, Seed, Pre-Seed
Israel, United States, Mali

Portfolio highlights

BloomX — Helping nature do its magic with the power of technology
MICA — MICA save lives & improve life quality. Our approach to the environmental and social dimensions is reflected in our commitment to United Nations Sustainable
NurExone Biologic — New approach to Spinal Cord Injury treatment based on view that intranasal exosome administration offers alternative to cell transplantation

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Avalo Therapeutics — Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.
Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Alterome Therapeutics — Transforming the lives of cancer patients, one alteration at a time. Our Mission is to discover precise therapies and inspire hope for individuals affected by cancer.

Neo Ventures is the first open-ended early stage investor, based in Eastern Europe. The founders have backed more than 30 startups and exited 10 successfully. We invest in game-changing businesses, without geographic limitations. We partner with exceptional founder teams to challenge incumbents in markets ripe for change or to create entirely newmarkets. Neo Ventures funds and then supports the founders in business planning, scaling operations, follow-on investments, making the best of each opportunity and dealing with hard situations. Our investment focus is on data analytics, computer vision and remote sensing addressing disruptive opportunities across the high-growth SpaceTech, BioTech and Security verticals.

Investment focus

Software, Artificial Intelligence, Aerospace
Seed, Funding Round, Series A
Israel, United Kingdom, Estonia

Portfolio highlights

EnduroSat — EnduroSat designs, builds and operates class-leading NanoSats for a range of commercial, exploration and science missions. We focus on inter-satellite connectivity and space data applications
Cyberwrite — TRUSTED BY INDUSTRY LEADERS One platform to accelerate value across the cyber insurance lifecycle THE LATEST FROM CYBERWRITE
GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

Pitango VC is a venture capital firm focused on health-tech (Pitango Health-tech) and growth (Pitango Growth) investments in startups around the world in domains such as vertical SaaS, digital health, deep tech, fintech and insurance technology, devops, generative AI, Web3, and food tech.With two offices in Israel, Pitango currently managesseveral venture funds totaling over $2.8 billion in committed capital. It has invested in more than 250 companies.

Investment focus

Software, Health Care, Information Technology
Series A, Series B, Series C
Israel, United States, China

Portfolio highlights

Variantyx — Based on clinical whole genome sequencing (WGS) and using a single patient sample, Variantyx's Genomic Unity® test identifies and reports all major variant types including small sequence changes, structural variants, mitochondrial variants and short tandem repeat expansions. This comprehensive test test eliminates the need for traditionalstep-wise, reiterative genetic testing.
Gina Life — At Nevia bio, we are focused on women's health. Our mission is to use innovative technologies to provide early detection of diseases through vaginal secretions analysis, enabled by Nevia's Machine Learning Platform.
Salvador Technologies — Salvador Technologies provides the world's fastest recovery from cyber-attacks and software/hardware malfunctions. Our innovative solution ensures the continuous operation of critical workstations and servers, eliminating downtime. Back to work in 30 seconds based on offline air-gapped sotrage.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.

Cancer Focus Fund is an investment firm that is dedicated to providing financial services to its clients. The company was founded by Ross Barrett.

Investment focus

Medical, Biotechnology, Health Care
Funding Round, Seed, Series A
Israel, United States

Portfolio highlights

ImmunoGenesis — We are rapidly translating the most cutting-edge discoveries from academic tumor immunology into drugs optimized for treating the majority of patients who have "cold" cancers refractory to currently available immunotherapy.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Nectin Therapeutics — NectinTX is a biotech company focused on unlocking the power of the immune system by developing a collection of next-gen immunotherapy agents.

FutuRx is the Israeli biotechnology accelerator that was established in 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation and Johnson & Johnson Development Corporation (JJDC) and Takeda Ventures Inc. following winning the tender of the Office of the Chief Scientist (OCS), Ministry of Economy, in Israel.The incubator willadvance new biotechnology products by identifying and nurturing early-stage life science innovation.FutuRx is located in the Weizmann Science Park in Ness Ziona (near the Weizmann Institute), Israel.

Investment focus

Biotechnology, Life Science, Biopharma
Seed, Funding Round
Israel

Portfolio highlights

Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.
Bsense Bio Therapeutics — Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. Bsense is pioneering a novel approach targeting multiple pain-related mechanisms using a single compound, to achieve greater efficacy and safety.

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Arancia International Inc is a part of Arancia Group in Mexico. We are long term investors in food, nutrition and biotechnology companies.

Investment focus

Health Care, Biotechnology, Life Science
Series A, Series B, Funding Round
Israel, United States, Malaysia

Portfolio highlights

NextFerm — NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value.At Nextferm, they aim to use their capabilities to lead this new and exciting world of better nutrition.
iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.

aMoon is a leading healthtech & life sciences venture capital firm.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, Israel, Switzerland

Portfolio highlights

Eleos Health — Automate documentation, alleviate provider burnout, and elevate care quality with the CareOps Automation platform from Eleos Health.
Better Life Partners — The Better Life Partners team helps people achieve healthier lives filled with purpose. We offer community support as well as virtual care.
Ibex Medical Analytics — Ibex Medical Analytics develops AI-driven clinical decision support tools that help pathologists deliver more efficient, metric-driven, objective and accurate diagnosis. It combines AI, data science, image analysis and machine learning technologies and applies them to cancer diagnostics in digital pathology.

Minrav provides engineering and construction services.

Investment focus

Health Care, Hospital, Wellness
Funding Round
Israel, Malaysia

Portfolio highlights

iwi Life — Algae is the ultimate source of Omega-3s. Research has proven that Omega-3s support cardiovascular health, a balanced mood, and healthy brain development.
Qualitas Health — Qualitas Health Group aims to serve patients through a network of 500 clinics by 2022 with quality healthcare services across the Asia Pacific.

Healthcare innovation wherever it originates.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, United Kingdom

Portfolio highlights

Moon Surgical — MastOR is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room.
Artera — Discover the power of Personalized Precision Medicine & AI Cancer Therapy with ArteraAI. Transforming cancer therapy through innovation.
ONL Therapeutics — ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

Genesis Park is a Houston-based private equity firm focusing on buyouts, partnering strategies with public corporations, and growth financing. We bring capital, commercial execution capabilities and a depth of experience in mergers and acquisitions.We are opportunistic within market sectors where we have depth and exposure. Those sectors includetelecommunications, energy technology and media. Energy technology is a rapidly expanding category, and our Houston base allows us to marry traditional and alternative techniques in upstream and downstream environments. Founded in 2000, Genesis Park has used discipline and patience to build value for our investors, regardless of prevailing market conditions. We are consistently active in our portfolio companies, listening, learning and adding value by working alongside management. While our preference is to partner with an existing management team, we commonly source additional talent to optimize the existing opportunity.

Investment focus

Manufacturing, Health Care, Natural Resources
Private Equity, Debt Financing, Funding Round
United States, Israel

Portfolio highlights

The Good Feet Store — Good Feet has been helping people with foot problems feel better and get back to living their lives. Personally fit with the arch support that meets their needs. Contact us now to see the available Good Feet Arch Support!
WESTCO GROUNDS — Westoco Provides Landscaping is a highly competitive industry, and Westco continues to thrive because it tailor services to specific client needs and deliver complete solutions with dependability,Rainbird facilitate quick responses and ressources.
Conditioned Air — Conditioned Air is South Florida's premier air conditioning contractor with 60 years of experience. Serving Naples, Venice, Ft. Myers, Englewood, Port Charlotte, Sarasota, Bradenton & Surrounding Areas.

fresh.fund is an Israeli pre-seed venture capital fund investing in early-stage startups across segments and verticals.We're built to partner with early-stage founders from day one, often as the company's first institutional investors. Our model is refreshingly simple: up to $300,000 in pre-seed funding within <4 weeks and follow-oncapital as necessary.Check out our portfolio here >> https://www.fresh.fund/portfolio. It's never too early to have a conversation about your startup.

Investment focus

Health Care, FinTech, E-Learning
Pre-Seed, Seed, Series A
Israel, United States, Norway

Portfolio highlights

Wisor — Propelling the supply chain industry into the digital age Wisor is a plug & play solution that provides a global automated quoting solution that allows freight forwarders to generate quotes and communicate with clients automatically Get a demo What took days now takes minutes Wisor is specifically designed to support and simplify the complexity of generating quotes
Peech — Peech, an automatic video editing tool, analyzes the verbal content of your video, edits it into a short & catchy version and enhances it with suited visual elements that attract your audience.
Ritual — Couple Goals Made Possible. Relationship Support For Busy People, Practical Tools & Expert Feedback

PeakBridge is an Alternative Investment Fund Manager and Investment Services Firm specialized in FoodTech.

Investment focus

Food and Beverage, Food Processing, Health Care
Seed, Series A, Funding Round
Israel, United States, United Kingdom

Portfolio highlights

Hyperplan — Hyperplan is a SaaS company whose mission is to assist industrial companies in dealing with crop production's increasing volatility. Hyperplan is a live, real-time software platform for crop and harvest management for all crops.
WNWN Food Labs — We're WNWN Food Labs and we love food. We're creating delicious, sustainable and ethical alternatives to unsustainable and ethically dubious foods. We're starting with cacao-free chocolate. Changing chocolate? It's Win-Win #alt-chocolate #altchocolate #alt-universe #altuniverse #alt-protein
The Mediterranean Food Lab — The Mediterranean Food Lab merge traditional fermentation and cutting-edge science, to produce natural plant-based flavor-bases for a wide range of meat replacement needs.

The Morningside group invests private-equity and venture capital in novel science and technology sectors and is committed to social responsibility.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

GaeaStar — The zero waste clay cup. GaeaStar is an engineering company developing sustainable multiple use products and technology.
Phage Pharm — Phage Pharm is a professional enterprise in the industrialization of bacteriophages.
Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.

Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech, medical device, and digital health technologies. Our synergistic healthcare investments are focused on creating innovations that benefit humanity and enhance medical care. We offer extensive experience, with a track record of successful healthcareinvestments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth. Arkin Holdings currently has a healthcare portfolio of $1.5 billion through its 5 investment arms. Its investors include a substantial amount of Israel’s top-tier institutional investors.

Investment focus

Biotechnology, Health Care, Medical Device
Series A, Seed, Funding Round
Israel, United States, Switzerland

Portfolio highlights

Percepto — Percepto is a developer of autonomous drone technology for inspection and surveillance.Drones hold the potential to disrupt multi-billion dollar industries including energy, security, insurance, agriculture, and more. Drones completely change the way inspection, measurement, surveillance, and deliveries are done today. Still, the main barrier tomaking them a must-have platform is the ability of drones to perform tasks autonomously.The company is at the forefront of redefining how industrial sites and critical infrastructure are holistically inspected and monitored, harnessing remote robotics to autonomously collect, aggregate, and analyze visual data.Leveraging its experience with Percepto Sparrow, the most deployed drone-in-a-box solution on the market, Percepto introduced Percepto AIM (Autonomous Inspection and Monitoring) the first end-to-end autonomous inspection and monitoring platform. Percepto AIM empowers the remote operation center of the future to assess risk, minimize downtime, drive efficiency, increase safety, and reduce operational costs.
MadeRight — We usher in a new era of sustainable fungi-based materials that deliver excellent performance. The future, as we see it, is a novel industrial chain based on biomaterials.
Revamp Medical — Revamp medical was founded in 2016 with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. Targeting a market of >1M annual admissions in the US with a direct cost of $65B, Revamp is set to deliver an easily adoptable solution using its patented temporary catheter, Doraya™.Revamp has a seasoned team ofprofessionals with a proven track record in leading multiple med-tech startups.

Remiges Ventures is a venture capital firm that focuses on groups and businesses in the Japanese academia and pharmaceutical industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Japan, Canada

Portfolio highlights

Immunis — Currently seeking participants for age-related muscle atrophy (sarcopenia) clinical trails
Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
Restore Vision — Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.

Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) and recently on the OTC (OTCBB : HADSY ) in order to allow public participation in the highly promising field of biotechnology.It serves as a precedent in biotech financing - for the first time, public investment is allowed toparticipate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").In addition to the public holdings (54%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (36%) and Consensus Business Group (http://www.consensusbusiness.com) (10%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 6 biotech companies - all based on inventions developed and owned by HU.HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine.

Investment focus

Biotechnology, Medical, Health Care
Funding Round, Series A, Series B
Israel

Portfolio highlights

ProtAb — ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for thetreatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.
KAHR medical — KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders.
Enlivex Therapeutics — Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis. The company develops an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, Crohn'sDisease, and other autoimmune and inflammatory disorders.The company's revolutionary approach is to induce immune tolerance by injecting apoptotic cells and facilitating their interaction with dendritic cells activates the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.Enlivex is an Israeli-based cell immunotherapy company established in October 2005 by Professor Dror Mevorach, a world-renowned expert on clearance of dying (apoptotic) cells.

ALIVE Israel HealthTech Fund is a pioneer mid-to-late stage HealthTech fund leveraging an exclusive ecosystem.

Investment focus

Health Care, Medical, Biotechnology
Series A, Funding Round, Series B
Israel, United States

Portfolio highlights

Append Medical — Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system.The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growingsegment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center.
Magenta Medical — Founded in October, 2012, Magenta Medical Ltd. is a privately held company that is engaged in the development of novel device solutions for the treatment of acute and chronic heart failure.
Gina Life — At Nevia bio, we are focused on women's health. Our mission is to use innovative technologies to provide early detection of diseases through vaginal secretions analysis, enabled by Nevia's Machine Learning Platform.

Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Seed, Series A
United States, Israel, The Netherlands

Portfolio highlights

InnoSIGN — We are passionate to bring to market our OncoSIGNal pathway activity profiling technology contributing to a better understanding of disease mechanisms in oncology. OncoSIGNal enables next generation precision medicine by translating molecular data into functional cell behavior.
Allyx Therapeutics — Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preservecognition in patients.
Avisi Technologies — Avisi Technologies is developing a nanotechnology-enabled defense against blindness from glaucoma.

NextLeap Ventures offers investors the opportunity to invest in early stage, Israeli high-tech startups, selected through its unique, highly vetted process.

Investment focus

Software, Big Data, Health Care
Seed, Series A, Funding Round
Israel, United States

Portfolio highlights

Cybord — Electronics components' quality, reliability, and highest level of traceability by leveraging visual AI and BigData
Enzymit — Enzymit's platform technology can build molecular machines that enable never before seen chemistry aiming to solve humanity's greatest challenges
ShieldIOT — ShieldIOT delivers innovative cybersecurity solutions that protect edge devices from security threats and operational risks. Their application-agnostic software solution enables device manufacturers and network operators to automatically secure existing and new devices, across multiple industries, with no need for any development resources orsecurity expertise.

Angel

Investment focus

Software, Information Technology, Artificial Intelligence
Pre-Seed, Seed, Series A
United States, United Kingdom, Singapore

Portfolio highlights

Vytal.ai — Vytal allows for brain health evaluation in minutes with just a laptop. Take control of your cognitive health.
Akhetonics — Creating the first all-optical RISC Processor
Greena World — In a world where travel connects us, we often overlook the impact we leave behind. Tourism accounts for over 8% of global CO2 emissions. Beyond environmental challenges like deforestation, pollution, and water scarcity, local communities also face pressure, experiencing changes in their traditions and ways of life.With expertise from SwanseaUniversity and the United Nations, our team recognised these challenges and envisioned a world where travel helps, not harms. Introducing Greena World. More than just a piece of technology, it's a guide for hotels and restaurants, helping them understand, improve, and share their impact on both the environment and local communities.The true beauty of embracing sustainability? The rewards. With the Greena Index, businesses can improve their sustainability and, in doing so, unlock a new market of over 100+ million eco-conscious travellers, boost revenues, and save on operating costs.The sustainable tourism sector is rapidly expanding, currently valued at $75B and witnessing a growth rate of 9.7% each year. While our initial focus is on hotels and restaurants, the Greena Index has ambitions to reshape the entire spectrum of the industry, from airlines to activities and destinations.Join us on a mission to transform the entire tourism industry for many generations to come.

Global impact fund focusing on biotech, medtech and agritech investments that make a difference

Investment focus

Medical, Health Care, Life Science
Funding Round
Israel

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.

OTV focuses on round A+ startups that aim to make a significant impact on people's lives. Our focus is on entrepreneurs with innovative ideas who are advancing the global state of well-being. Come join the digital health revolution, and be a part of transforming the healthcare industry.

Investment focus

Health Care, Medical, Artificial Intelligence
Series A, Series B, Seed
United States, Israel, Ghana

Portfolio highlights

Scopio — Buy & sell images on the largest Solana Photography NFT Marketplace. Find high-quality stock images & hire artists from around the world.
Scopio Labs — Click here to learn more about Scopio Labs AI Driven Digital Platform for Cell Morphology.
Stake — Renters earn Cash back for rent. Building operators outperform the market. That's the Stake win-win. Find out how we're building the financial tools for the next generation of rentals.

Investment strategy is spearheaded by a deep expertise in identifying companies from inception and building global industry leaders.

Investment focus

Software, Cyber Security, Enterprise Software
Series A, Series B, Seed
United States, Israel, United Kingdom

Portfolio highlights

Akeyless Security — The #1 Vault Alternative secures credentials, certificates and keys securely and with ease across multi-cloud environments.
BioBetter — BioBetter is a foodtech company that develops plant-based platforms for the production of complex growth factors used in cultivated meat. The company was founded in 2015 and is headquartered in Israel.
Chain Reaction — Chain Reaction is engineering the future of disruptive blockchain and privacy technologies by accelerating compute and mining hardware performance.

financial holding company / investments

Investment focus

FinTech, Finance, Payments
Seed, Pre-Seed
The Netherlands, Israel

Portfolio highlights

Wakuli — It's called specialty coffee. Roasted lighter to enhance all the exciting flavours. To really taste them it's important to drink fresh. That's why we send our mailbox-friendly coffee within one week after roasting. And always with a better price for the farmers - thanks to you.
Diptera — Developing technology to fight mosquitoes with mosquitoes.
Flow — Flow is FinTech 3.0: It let's you automate payments between your bank accounts and wallets. Based on triggers and actions you can transfer your money automatically to the accounts you choose. Use Flow to automate a budgetting system, your investing, buying crypto or to distribute your money the way you like it. Where the previous generationpayment companies needed to build and maintain expensive payment rails, Flow focusses on leveraging Open Banking. People trust Flow to help with their cashflow automation.

Sectoral is specialized in managing equities globally in the healthcare sector. Founded in October 2000, we are SEC-registered as an investment advisor. 100% employee-owned, we have offices in Montreal, Geneva, and Hong Kong.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Post-IPO Equity
United States, United Kingdom, France

Portfolio highlights

CurvaFix — Curvafix is the only intramedullary implant that follows the natural curvature of the pelvis. Continue reading to learn how the Curvafix implant works!
Boundless Bio — Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.Boundless Bio was founded in 2018 and isheadquartered in La Jolla, California.
LENZ Therapeutics — LENZ Therapeutics is is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Seed, Series A, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
Violet Therapeutics — Violet Therapeutics is a healthcare company that operates in stealth mode.

Investing with conviction in visionary, technical founders inventing the future.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Pre-Seed, Series A
United States, Canada, Israel

Portfolio highlights

Genialis — Genialis is a precision medicine data science company focused on new ways to treat disease. Blending computational biology and AI-based methods, Genialis merges and models data at the intersection of clinical and translational medicine and drug discovery. Genialis is trusted by biopharma and big pharma alike, to validate targets, predict biomarkersand optimally position novel drugs. Together, Genialis and its partners are bringing improved solutions to drug discovery to change people's lives.
Bedrock Energy — Bedrock Energy is developing drilling technology and advanced subsurface simulation software to enable geothermal heating and cooling. The company develops autonomous drilling technology and advanced subsurface simulation software to make geothermal heating and cooling more widespread, affordable, and accessible.
Blumen Systems — Blumen is an early-stage technology company building software to streamline the regulatory challenges associated with upstream natural resources production in the US. We are focused on producers building and utilizing land-based assets powering the energy transition including carbon sequestration, geothermal, critical minerals, hydrogen, and RNGprojects.

Rationalwave Capital Partners is a venture capital firm investing in technology companies both public and private. The firm is located in New York and founded by Mark Rosenblatt in 2003.

Investment focus

Machine Learning, Artificial Intelligence, Analytics
Seed, Pre-Seed, Funding Round
United States, Israel, Trinidad and Tobago

Portfolio highlights

Aromyx — Aromyx pioneers the creation of tastes and smells using a quantitative measurement system developed with biotechnology, data science, and AI.
Brij — With one-touch, BRIJ allows consumers to gain product info, care instructions and discounts while you gain a deeper understanding of your consumer. Apps, paper manuals and hassles not required.
BactoByte LTD — BactoByte aims to empower caregivers with one-hour bacterial diagnostics and antibiotic screening capability to improve outcomes, reduce mis-diagnostics, and lower health care costs.Based on a proprietary novel basic method, BactoByte’s assay delivers precise and cost-effective identification and direct antibiotics susceptibility testing with80-90% improvement of standard turnaround time.Time reduction, sensitivity, and specificity results in decreased mortality rates, fewer hospital days, and avoidance of associated costs of $1K-50K per patient.BactoByte has technology validation and partnerships with leading medical centers.

A Diversified Company focused on multiple area of the cannabis hemp and CBD industry.

Investment focus

AgTech, Medical, Cannabis
Series A
Israel

Portfolio highlights

GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

SICAR

Investment focus

Medical, Health Care, Life Science
Series C, Funding Round
Israel, Germany

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

RMGP Biopharma Investment Fund is an investment Fund

Investment focus

Biotechnology, Biopharma, Health Care
Seed, Series B, Funding Round
Israel

Portfolio highlights

Ramino Bio — Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.Ramino has received funding totaling about $3.3 million since its beginning from the FutuRx biotech incubator, which is supported by the Israeli Innovation Authority, Takeda, J&J, OrbiMed, and RMPG. By speeding up their disintegration, our exclusivetechnology lowers the extra BCAA that is floating around.
Pi Therapeutics — Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and hasoperated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.
Protekt Therapeutics — ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital Their extensive experience in academic science, clinical and commercial strategy, company operations, mergers and acquisitions, venture capital and corporate financeputs them in an especially strong position to build and support a wide range of businesses and technologies.Arix Bioscience has privileged agreements with leading universities in the UK, Europe and Australia, providing direct access to innovative new technologies. They also have access to a broad range of research projects from US academic institutions.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, France, Israel

Portfolio highlights

Ensoma — Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As aresult, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.
Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Disc Medicine — We are restoring regulation of hepcidin - the link between genetics and erythropoiesis - to create new therapies for patients with inherited and acquired anemias.

Talisman Capital Partners operates as a private investment company.

Investment focus

Information Services, Pet, News
Series A, Seed, Series B
United States, Israel, Hong Kong

Portfolio highlights

Bond Vet — We offer compassionate, thorough, & friendly pet care in a warm, comfortable environment. Walk in or book online.
Prilenia — Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston.
qServe Communications — At qServe Communications, it is their unique vision to be a one-stop source for all your maintenance and development needs. They understand the difficulty of locating reliable companies to meet all of your infrastructure requirements. qServe has built an answer to this problem, a national service network of in-house employees to deliver qualitymanagement, installation, erection, inspection and maintenance services to the communications industry.With their full spectrum of project and program management services, they drive your project from start to finish, becoming an integral part of your development team. Many of qServe Communications crews and staff bring many years of valuable experience in the development of communications systems and infrastructures. From Program and Project Management to in-house installation and maintenance services, qServe will work diligently to ensure your project's success.qServe has performed thousands of projects for clients including: AT&T Wireless Services, Alltel Mobile, Nextel, Sprint, Omnipoint, Bell Atlantic Mobile, Teligent, Metricom, American Tower, Crown Castle and SBA Communications Corporation.

Trust Ventures is a venture capital firm that focuses on startups and provides knowledge and expertise in incumbent-heavy industries. The firm was founded in 2018 and is based in Austin, Texas, United States.

Investment focus

Information Technology, Health Care, Software
Seed, Series A, Series B
United States, Brazil, Israel

Portfolio highlights

Harbor — Harbor is an infant care technology company that focuses on transforming the way to take care of young children and their families.
Antora Energy — Antora converts low-cost, intermittent renewable electricity into a reliable, on-demand source of zero-emissions industrial heat and power.
Black Ore Technologies — Black Ore's Tax Autopilot is the first AI tax platform for CPAs, offering complete 1040 tax preparation automation to tax professionals, so they can focus on growing their firm.

Grove Ventures is a leading early-stage venture capital fund in Israel. It partners early with exceptional Israeli founders who believe th...

Investment focus

Artificial Intelligence, Machine Learning, Software
Seed, Series A, Series B
Israel, United States

Portfolio highlights

NoTraffic — NoTraffic has developed the first AI-powered traffic signal platform that connects road...
Wing Cloud — Wing Cloud tames cloud complexity through a unified programming and operational model that works across all providers and services.
DeepChecks — Continuous validation for machine learning. Validate and monitor your data and models during training, production and new version releases.

Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI)

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Israel, United States

Portfolio highlights

Sight Diagnostics — Combining AI and breakthrough hardware to bring lab-quality CBC results to the doctor's office.
Cadent Therapeutics — Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts.
Elicio Therapeutics — Elicio ground-breaking Amphiphile technology is engineering potent vaccines and immunotherapies to defeat an array of aggressive cancers.

TPY Capital is a Tel Aviv based early state VC, investing in some of Israel’s most talented entrepreneurs. They are active investors who typically lead rounds in the areas we invest in, which include data and analytics, digitization and human augmentation, fintech, and frontier tech such as quantum computing.

Investment focus

Software, Artificial Intelligence, Big Data
Seed, Series A, Series B
Israel, United States, France

Portfolio highlights

Tabnine — Tabnine is an AI code-completion tool that helps developers worldwide write better code faster.
Konnecto — Market Intelligence | Konnecto | Prescriptive Analytics Konnecto is a GTM Intelligence Platform that provides brands with an ongoing blueprint on how to increase online sales and improve marketing ROI
Kodem Security — Providing users with runtime intelligence to grasp the relevant application risks.

Investment banking boutique based in Tel Aviv since 1978.

Investment focus

AgTech, Medical, Cannabis
Series A
Israel

Portfolio highlights

GemmaCert — The easy-to-use GC-PRO by GemmaCert for quick and accurate potency analysis of cannabis and hemp, including for THC, CBD, and CBG.

RM Global is an investment banking and strategic advisory firm dedicated to creating unique value for its clients and investors. We specialize in Life Sciences, including pharmaceuticals, medical devices, biotechnology, healthcare IT/digital health, and diagnostics. Our broad international reach includes the Americas, Europe, Israel, and Asia.Since 1992, our diverse team of accomplished professionals has worked closely with life science companies ranging from start-ups to multinationals, providing unbiased strategic and financial advice, based upon our comprehensive industry experience. Several of our partners were senior management of Roberts Mitani, which completed over $3 billion in M&A and strategic transactions and raised over $200 million in private growth and venture capital for clients. We take pride in our long term relationships with our clients that span many years.We leverage our unique global network of leading corporations, investment funds, institutional and strategic investors, family offices, industry experts and management teams to source and execute transactions that build new opportunities for our clients worldwide.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B
Israel, United States

Portfolio highlights

BIOMx — Developing natural and engineered phage therapies to eradicate harmful bacteria in chronic diseases.
Mitoconix Bio — Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism,keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death.Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
ImmPACT Bio — ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.

Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Funding Round, Series A
Israel, Singapore, United Kingdom

Portfolio highlights

Insectta — Insectta was founded in 2017 and produces materials from insects which can be applied across industries such as agrifood, pharmaceutical and electronics.
Celleste Bio — Celleste is a business that specializes in employing cell culture techniques to produce high-value cocoa ingredients, removing the need for cocoa trees to be grown.
ViAqua Therapeutics — ViAqua is developing the first orally administered treatment in aquaculture to stop diseases from developing and to prevent viral epidemics.

Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.

Investment focus

Biotechnology, Medical, Biopharma
Series B, Series A, Funding Round
United States, Italy, United Kingdom

Portfolio highlights

NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
Sibylla Biotech — Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
On Target Laboratories — ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.

We focus on advances in medical technology and digital health to change the face of healthcare.

Investment focus

Health Care, Medical, Biotechnology
Series B, Series C, Series A
United States, Israel

Portfolio highlights

SubjectWell — SubjectWell connects patients with chronic health conditions to trials and treatments. Since 2012, SubjectWell has been registering tens of millions of healthcare-motivated patients with known conditions. At SubjectWell, we already have the patients you need.
Valera Health — Valera Health believes that mental health care should be simple, accessible, & affordable. Our Telehealth platform connects therapists & psychiatrists with our patients online.
Alto Neuroscience — Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most.

Arc Impact is a venture capital firm.

Investment focus

Health Care, Food and Beverage, AgTech
Seed, Pre-Seed
Israel, United States, United Kingdom

Portfolio highlights

Behavidence — Behavidence is a mental health application that generates a daily mental health score. It compares your digital behavior to other people with anxiety, depression and ADHD.
MadeRight — We usher in a new era of sustainable fungi-based materials that deliver excellent performance. The future, as we see it, is a novel industrial chain based on biomaterials.
Virtual Internships — The only platform that provides guaranteed remote internships in your chosen industry and region to gain the skills employers seek.

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate